Claims for Patent: 8,231,876

Summary for Patent: 8,231,876

Title:	Purified antibody composition
Abstract:	The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Inventor(s):	Wan; Min M. (Worcester, MA), Avgerinos; George (Sudbury, MA), Zarbis-Papastoitsis; Gregory (Watertown, MA)
Assignee:	Abbott Biotechnology Ltd. (Hamilton, BM)
Application Number:	12/882,601
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,231,876
Patent Claims:	1. A host cell protein (HCP)-reduced antibody preparation produced by a method comprising: applying a mixture comprising an antibody and at least one HCP to a cation exchange resin in an equilibration buffer, wherein greater than 30 grams of antibody per liter of cation exchange resin are applied; washing HCP from the cation exchange resin with a plurality of wash steps comprising a first wash and a second wash, wherein there is an increase in conductivity from the first wash to the second wash; eluting the antibody from the cation exchange resin with an elution buffer to form a first eluate; applying the first eluate to an anion exchange resin, wherein prior to applying the first eluate to the anion exchange resin, pH and conductivity of the first eluate are adjusted to be substantially similar to pH and conductivity of the anion exchange resin; and obtaining a first flowthrough comprising the antibody, such that the HCP-reduced antibody preparation is obtained, wherein the antibody is an isolated human anti-TNF.alpha. antibody that dissociates from human TNF.alpha. with a K.sub.d of 1.times.10.sup.-8 M or less and a K.sub.off rate constant of 1.times.10.sup.-3 s.sup.-1 or less, both determined by surface plasmon resonance, and neutralizes human TNF.alpha. cytotoxicity in a standard in vitro L929 assay with an IC.sub.50 of 1.times.10.sup.-7 M or less, and wherein the HCP-reduced antibody preparation comprises no greater than about 70 ng of HCP per mg of antibody as measured by a HCP ELISA and a cathepsin L activity of no greater than about 3.0 RFU/s/mg antibody. 2. A pharmaceutical composition comprising the HCP-reduced antibody preparation of claim 1, and a pharmaceutically acceptable carrier. 3. A pharmaceutical composition comprising an isolated human anti-TNF.alpha. antibody that dissociates from human TNF.alpha. with a K.sub.d of 1.times.10.sup.-8 M or less and a K.sub.off rate constant of 1.times.10.sup.-3 s.sup.-1 or less, both determined by surface plasmon resonance, and neutralizes human TNF.alpha. cytotoxicity in a standard in vitro L929 assay with an IC.sub.50 of 1.times.10.sup.-7 M or less, and a pharmaceutically acceptable carrier, wherein the composition contains a level of HCP no greater than about 70 ng of HCP per mg of antibody as measured by an HCP ELISA and a cathepsin L activity of no greater than about 3.0 RFU/s/mg antibody. 4. The pharmaceutical composition of claim 3, wherein the level of HCP comprises no greater than 13 ng of HCP per mg of antibody as measured by a HCP ELISA. 5. The pharmaceutical composition of claim 3, wherein the level of HCP comprises no greater than 5 ng of HCP per mg of antibody as measured by a HCP ELISA. 6. The pharmaceutical composition of claim 3, wherein the anti-TNF.alpha. antibody, or antigen-binding portion thereof, has the following characteristics: comprises a light chain variable region comprising a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; a light chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5; and a light chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable reason comprising a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, a heavy chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a heavy chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8. 7. The pharmaceutical composition of claim 3, wherein the anti-TNF.alpha. antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 8. The pharmaceutical composition of claim 3, wherein the anti-TNF.alpha. antibody is adalimumab, or an antigen-binding portion thereof. 9. The pharmaceutical composition of claim 3, wherein the composition has an antibody concentration of 50 mg/mL. 10. An article of manufacture comprising a packaging material and an adalimumab formulation, wherein the adalimumab formulation comprises no greater than about 70 ng of HCP per mg of adalimumab as measured by an HCP ELISA and a cathepsin L activity of no greater than about 3.0 RFU/s/mg adalimumab. 11. The article of manufacture of claim 10, wherein the adalimumab formulation comprises no greater than 13 ng of HCP per mg of adalimumab. 12. The article of manufacture of claim 10, wherein the adalimumab formulation comprises no greater than 5 ng of HCP per mg of adalimumab. 13. The article of manufacture of claim 10, wherein the adalimumab formulation has an adalimumab concentration of 50 mg/mL.

Details for Patent 8,231,876

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002		2026-04-05
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008		2026-04-05
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013		2026-04-05